Samsung Biologics (207940) Q4 2025 earnings summary

Executive summary

• Achieved 30% year-over-year revenue growth in 2025, driven by Plant 4 ramp-up and full utilization of Plants 1–3, with favorable FX impact.

• Completed equity spin-off, resumed share trading in November, and acquired a U.S. manufacturing facility to enhance global footprint.

• Secured three contracts over KRW 1T in 2025, including a major deal with a European pharma, and cumulative orders surpassed USD 21.2B.

Financial highlights

• Q4 2025 revenue: KRW 1,286B (+35% YoY); operating profit: KRW 528B (OPM 41.1%).

• Full-year 2025 revenue: KRW 4,557B (+30% YoY); operating profit: KRW 2,069B (OPM 45.4%).

• Net profit for 2025: KRW 1,784B (+701B YoY); EBITDA margin improved to 53.5%.

• Gross profit for 2025: KRW 2,517B; SG&A: KRW 447B.

Outlook and guidance

• 2026 consolidated revenue projected to grow 15–20% year-over-year, not including additional U.S. facility contributions.

• Continued focus on expanding CDMO capacity and global operations.